Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Mouse monoclonal [BU12] to CD19
- Suitable for: Flow Cyt
- Reacts with: Human
Product nameAnti-CD19 antibody [BU12]
See all CD19 primary antibodies
DescriptionMouse monoclonal [BU12] to CD19
Tested applicationsSuitable for: Flow Cytmore details
Unsuitable for: IHC-P
Species reactivityReacts with: Human
- Flow Cyt: Human peripheral blood mononuclear cell.
This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact firstname.lastname@example.org.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 0.05% BSA, 40% Glycerol (glycerin, glycerine)
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab254170 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Flow Cyt||Use a concentration of 1.07 µg/ml.|
FunctionAssembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation.
Involvement in diseaseDefects in CD19 are the cause of immunodeficiency common variable type 3 (CVID3) [MIM:613493]; also called antibody deficiency due to CD19 defect. CVID3 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B cells is usually in the normal range, but can be low.
Sequence similaritiesContains 2 Ig-like C2-type (immunoglobulin-like) domains.
modificationsPhosphorylated on serine and threonine upon DNA damage, probably by ATM or ATR. Phosphorylated on tyrosine following B-cell activation.
- Information by UniProt
- Antibody deficiency due to defect in CD19 antibody
- Antibody deficiency due to defect in CD19, included antibody
- AW495831 antibody
Flow cytometric analysis of human peripheral blood mononuclear cell (PBMC) cells labelling CD19 with ab254170 at 1.07 µg/mL, Right compared with a Mouse monoclonal IgG / Left isotype control and an unlabelled control (cells without incubation with primary antibody and secondary antibody) (Blue). Goat anti mouse IgG (Alexa Fluor® 488, ab150113) at 1/2000 dilution was used as the secondary antibody. Cells were stained with mouse IgG (Left) or ab254170 (Right). Then stained with anti-CD3 conjugated to Alexa Fluor® 647. Gated on viable cells.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab254170 has been referenced in 4 publications.
- Bortolotti M et al. High in Vitro Anti-Tumor Efficacy of Dimeric Rituximab/Saporin-S6 Immunotoxin. Toxins (Basel) 8:N/A (2016). PubMed: 27338475
- Flavell DJ et al. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma. Br J Haematol 134:157-70 (2006). PubMed: 16771848
- Behr S & Schriever F Engaging CD19 or target of an antiproliferative antibody 1 on human B lymphocytes induces binding of B cells to the interfollicular stroma of human tonsils via integrin alpha 4/beta 1 and fibronectin. J Exp Med 182:1191-9 (1995). PubMed: 7595190
- Callard RE et al. CD19 regulation of human B cell responses. B cell proliferation and antibody secretion are inhibited or enhanced by ligation of the CD19 surface glycoprotein depending on the stimulating signal used. J Immunol 148:2983-7 (1992). PubMed: 1374445